|
|
|
| Effect of Irbesartan Combined with Amiodarone on the Levels of Serum Inflammatory Factors Myocardial Enzymes and NT-proBNP in Patients with Paroxysmal Atrial Fibrillation |
| JI Ping, WANG Ping, WU Luling |
| General Hospital of Jianghan Oilfield, Hubei Qianjiang 433100, China |
|
|
|
|
Abstract Objective: To analyze the effects of irbesartan combined with amiodarone on the levels of serum inflammatory factors, myocardial enzymes and amino terminal B-type N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with paroxysmal atrial fibrillation. Methods: 90 patients with paroxysmal atrial fibrillation were randomly divided into observation group and control group according to the simple random number table method after numbering with admission sequence, 45 cases in each group. The control group was given routine treatment and amiodarone, the observation group was given irbesartan combined with amiodarone treatment. The followed-up last for 12 months in both groups. The number of atrial fibrillation, maintenance rate of sinus rhythm, cardiac function [left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVDD), left ventricular posterior walldepth (LVPW), P wave dispersion (PD)], serum inflammatory factors, myocardial enzymes [Creatine kinase isoenzyme (CK-MB), cardiac troponin I (cTnI)], NT-proBNP levels and incidence of adverse events in the two groups were recorded. Results: The number of atrial fibrillation in the observation group was less than that in the control group at 6 months and 12 months after treatment, while the maintenance rate of sinus rhythm was higher than that in the control group (P<0.05). At the end of treatment, the LVEF in the observation group was higher than that in the control group, while the LVDD, LVPW and PD were smaller than those in the control group (P<0.05). The levels of serum HSP27, hs-CRP, IL-6, CK-MB, cTnI and NT-proBNP in the observation group were lower than those in the control group after treatment (P<0.01). The incidence of adverse events in the observation group was 24.44%, slightly higher than that in the control group (17.78%) (P>0.05). Conclusion: The combination application of irbesartan combined with amiodarone for patients with paroxysmal atrial fibrillation can significantly reduce the number of atrial fibrillation, improve maintenance rate of sinus rhythm and cardiac function, reduce the levels of inflammatory factors and NT-proBNP, restore myocardial enzymes to normal. It is safe and reliable.
|
|
|
|
|
|
[1] Aleong RG,Sauer WH,Davis G,et al.New-onset atrial fibrillation predicts heart failure progression[J].Am Med,2014,127(10):963~971.
[2] Lamberts M,Lip GY,Ruwald MH,et al.Antithrombotic treatment in patients with heart failure and associated atrial fibrillation and vascular disease:a nation wide cohort study[J].Am Coll Cardiol,2014,63(24):2689~2698.
[3] 刘寿东.厄贝沙坦氢氯噻嗪联用胺碘酮对持续性房颤转复后维持窦性心律的影响[J].现代中西医结合杂志,2014,23(14):1538~1540.
[4] 张承中.厄贝沙坦配合胺碘酮对慢性心力衰竭合并阵发性房颤患者P波最大时限及P波离散度的影响[J].解放军预防医学杂志,2016,34(4):308.
[5] 韩晓霞,郭庆玲,冯巧飞,等.1例甲亢并发极快速型房颤患者的护理[J].标记免疫分析与临床,2016,23(5):590~591.
[6] 卢红艳,宁伟明,苏新养,等.血清CRP、Fib及NT-proBNP对慢性房颤并发早期心衰的诊断价值[J].海南医学,2017,27(8):1271~1273.
[7] 郑宏健,祝长芝.厄贝沙坦联合胺碘酮对慢性心力衰竭患者P波离散度与阵发性心房颤动的影响[J].心脑血管病防治,2017,17(3):182~184.
[8] 王苗苗.胺碘酮联合厄贝沙坦治疗老年CHF伴阵发性心房颤动的效果观察[J].中西医结合心脑血管病杂志,2018,16(13):1848~1851.
[9] 李麟,王永莉,曹佳宁,等.依那普利联合胺碘酮治疗阵发性心房颤动效果观察[J].人民军医,2016,59(1):36~37. |
|
|
|
2019, Vol. 25 
